United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Rating of “Moderate Buy” from Analysts

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have received an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $619.4167.

UTHR has been the topic of several research reports. UBS Group raised their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Raymond James Financial started coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Royal Bank Of Canada lowered their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $554.61, for a total transaction of $5,268,795.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at $22,468,914.93. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,960,240.32. The trade was a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 632,718 shares of company stock valued at $356,533,651 over the last 90 days. 8.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC acquired a new stake in shares of United Therapeutics during the fourth quarter valued at about $26,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC lifted its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in United Therapeutics in the fourth quarter valued at about $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 1.6%

United Therapeutics stock opened at $555.91 on Friday. United Therapeutics has a 52-week low of $272.12 and a 52-week high of $609.35. The firm has a fifty day moving average of $558.71 and a 200-day moving average of $527.64. The firm has a market capitalization of $23.60 billion, a P/E ratio of 20.52, a PEG ratio of 1.80 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the previous year, the firm posted $6.63 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. On average, research analysts expect that United Therapeutics will post 26.63 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.